12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sapacitabine: Updated Phase II data

Cyclacel presented updated OS data from 3 arms in an open-label, U.S. Phase II trial in 63 elderly patients with MDS evaluating sapacitabine. Specifically, updated median OS was 291 days, up from 240 days, in patients receiving twice-daily 200 mg sapacitabine for 7 days; 274 days, down from 290 days, in patients receiving once-daily 300 mg sapacitabine for 7 days; and 227 days, up from 153 days, for patients receiving once-daily 100 mg sapacitabine for 5 days per week for 2 weeks in 4-week cycles. Median OS for...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >